C L Wagner

Summary

Publications

  1. ncbi Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade
    C L Wagner
    Centocor, Inc, Malvern, PA 19355, USA
    Dev Biol (Basel) 112:37-53. 2003
  2. ncbi Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
    M A Mascelli
    Department of Clinical Pharmacology, Centocor Inc, Malvern, PA, USA
    Circulation 97:1680-8. 1998
  3. ncbi Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model
    T Kadokami
    Cardiovascular Institute of the University of Pittsburgh Medical Center Health System, Pittsburgh, PA, USA
    Circulation 104:1094-7. 2001
  4. ncbi Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis
    P C Taylor
    Kennedy Institute of Rheumatology Division, Imperial College School of Medicine, London, UK
    Arthritis Rheum 50:1107-16. 2004
  5. ncbi Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis
    P C Taylor
    Kennedy Institute of Rheumatology Division, Imperial College School of Medicine, 1 Aspenlea Road, London W6 8LH, UK
    Arthritis Rheum 54:47-53. 2006

Collaborators

Detail Information

Publications5

  1. ncbi Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade
    C L Wagner
    Centocor, Inc, Malvern, PA 19355, USA
    Dev Biol (Basel) 112:37-53. 2003
    ..In addition, the antibodies induced to infliximab are specific for infliximab, and do not cross-react with other currently available therapeutic antibodies...
  2. ncbi Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
    M A Mascelli
    Department of Clinical Pharmacology, Centocor Inc, Malvern, PA, USA
    Circulation 97:1680-8. 1998
    ..The purpose of the present study was to establish the pharmacodynamic profile and platelet-bound life span of abciximab...
  3. ncbi Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model
    T Kadokami
    Cardiovascular Institute of the University of Pittsburgh Medical Center Health System, Pittsburgh, PA, USA
    Circulation 104:1094-7. 2001
    ..CONCLUSIONS: Blockade of TNF-alpha bioactivity by antibody therapy may both preserve cardiac function and partially reverse pathological changes in congestive heart failure...
  4. ncbi Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis
    P C Taylor
    Kennedy Institute of Rheumatology Division, Imperial College School of Medicine, London, UK
    Arthritis Rheum 50:1107-16. 2004
    ....
  5. ncbi Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis
    P C Taylor
    Kennedy Institute of Rheumatology Division, Imperial College School of Medicine, 1 Aspenlea Road, London W6 8LH, UK
    Arthritis Rheum 54:47-53. 2006
    ..To compare the impact of immediate and delayed introduction of anti-tumor necrosis factor therapy on inflammation and structural damage in methotrexate (MTX)-treated patients with early rheumatoid arthritis (RA)...